As the review concludes, The effect of GLP-1 analogues on the gut microbiota may have a positive impact on the long-term treatment of diabetes. However, further work is needed
Medications called GLP-1 receptor agonists (GLP-1 RAs) mimic this hormones effect
Different mechanisms of action may elicit fewer GI adverse events, which are seen in ~40% of patients on semaglutide or tirzepatide
In March 2026, a Foundayo is notable not only for its oral formulation but also for being among the first medications approved under the FDAs new Additionally, unlike other oral GLP-1s, it does not require the fasting and water restrictions associated with oral semaglutide, potentially making it more accessible
adults without diabetes using these drugs
Overall, through direct anti-proliferative effects, metabolic regulation and immunomodulation (121,174,207,209), GLP-1RAs demonstrate promising potential for clinical translation in HCC management